Find any stock by ticker or company name
NYQ – Real Time Price. Currency in USD
35.81
-0.03 (-0.08%)
At close: May 12, 2026, 4:00 PM EDT
35.91
+0.08 (0.21%)
Pre-market: May 13, 2026, 8:16 AM EDT
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
| Name | Position |
|---|---|
| Dr. Eric A. Hughes M.D., Ph.D. | Executive VP of Global R&D and Chief Medical Officer |
| Kathleen Veit | Senior Vice President, Global Compliance & Ethics Officer |
| Mr. Amir Weiss | Senior VP & Chief Accounting Officer |
| Mr. Brian Savage | Interim Chief Legal Officer |
| Mr. Christopher J. Stevo CFA | Senior Vice President of Investor Relations & Competitive Intelligence |
| Mr. Eliyahu Sharon Kalif | Executive VP & CFO |
| Mr. Evan Lippman M.B.A. | Executive Vice President of Business Development |
| Mr. Matthew Shields | Executive Vice President of Global Operations |
| Mr. Richard D. Francis | President, CEO & Director |
| Ms. Christine Fox | Executive VP of US Commercial & Head of Innovative Franchise |
| Date | Type | Document |
|---|---|---|
| 2026-04-29 | 8-K | f8k_042926.htm |
| 2026-04-29 | 10-Q | d115083d10q.htm |
| 2026-03-31 | DEFA14A | d13996ddefa14a.htm |
| 2026-02-03 | 10-K | d93612d10k.htm |
| 2026-01-28 | 8-K | f8k_012826.htm |
| 2026-01-12 | 8-K | f8k_011126.htm |
| 2025-12-11 | 8-K | d46386d8k.htm |
| 2025-11-05 | 10-Q | d920125d10q.htm |
| 2025-07-30 | 10-Q | d939815d10q.htm |
| 2025-06-05 | 8-K | d90930d8k.htm |